Visceral Fat and Ossification of the Posterior Longitudinal Ligament
JBJS Open Access · 2025-10 · 10 (4)
DOI: 10.2106/jbjs.oa.25.00195 ↗Kurz gefasst
Fachartikel in der Zeitschrift JBJS Open Access, 2025-10. Verfasst von Tomoya Sato und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Ossification of the posterior longitudinal ligament (OPLL) is relatively common in East Asian populations, with a recently revealed link to obesity. However, evidence linking OPLL with visceral fat obesity, which is prevalent in the Asian population, is insufficient. We aimed to examine the association between visceral fat obesity and the development of OPLL.
Methods
In a single-center case-control study, data were collected from 120 Japanese patients diagnosed with OPLL and 91 controls without spinal ligament ossification identified during health screenings. From 2020 to 2023, all participants underwent computed tomography to assess visceral fat content and spinal ligament ossification. OPLL was classified as localized (cervical spine) or diffuse (thoracic/lumbar spine). Multivariable logistic regression was conducted to assess the effect size (odds ratio [OR]) of body mass index on the incidence of OPLL and to compare outcomes between groups with a high and low visceral/subcutaneous fat area (V/S) ratio.
Results
The proportion of patients with visceral fat obesity was significantly higher in both the localized and diffuse OPLL groups than in the controls (58.9% vs. 64.1% vs. 25.2%, p < 0.05). Patients with OPLL had a higher rate of comorbid visceral fat obesity than the propensity score–matched controls did (56.8% vs. 18.1%, p < 0.001). The effect of BMI on the development of diffuse OPLL was 2.6-fold greater in the high V/S ratio group (OR, 9.50; 95% confidence interval [CI], 2.11 to 42.71) than in the low V/S ratio group (OR, 3.56; 95% CI, 1.51-8.37).
Conclusions
Visceral fat obesity was associated with the development of OPLL, particularly diffuse OPLL. The modifying effect of visceral fat accumulation with overweight status was more strongly associated with diffuse OPLL than was that of subcutaneous fat combined with an overweight status. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
- Spine Center, Hakodate Central General Hospital, Hakodate, Hokkaido, Japan.
ORCID-Profile: Tomoya Sato, Tsutomu Endo, Yoshinao Koike, Hideki Sudo, M Alaa Terkawi, Huohuo Xue, Ryo Fujita, Soya Miura, Ryota Suzuki, Yukitoshi Shimamura, Masahiro Kanayama, Ken Kadoya, Katsuhisa Yamada, Daisuke Ukeba, Misaki Ishii, Norimasa Iwasaki
Zitieren
APA
Sato, T., Endo, T., Koike, Y., Sudo, H., Terkawi, M. A., Xue, H., Fujita, R., Miura, S., Suzuki, R., Shimamura, Y., Kanayama, M., Kadoya, K., Yamada, K., Ukeba, D., Ishii, M., & Iwasaki, N. (2025). Visceral Fat and Ossification of the Posterior Longitudinal Ligament. JBJS Open Access, 10(4). https://doi.org/10.2106/jbjs.oa.25.00195
Vancouver
Sato T, Endo T, Koike Y, Sudo H, Terkawi MA, Xue H, et al. Visceral Fat and Ossification of the Posterior Longitudinal Ligament. JBJS Open Access. 2025;10(4). doi:10.2106/jbjs.oa.25.00195
BibTeX
@article{Sato2025,
author = {Sato, Tomoya and Endo, Tsutomu and Koike, Yoshinao and Sudo, Hideki and Terkawi, M Alaa and Xue, Huohuo and Fujita, Ryo and Miura, Soya and Suzuki, Ryota and Shimamura, Yukitoshi and Kanayama, Masahiro and Kadoya, Ken and Yamada, Katsuhisa and Ukeba, Daisuke and Ishii, Misaki and Iwasaki, Norimasa},
title = {Visceral Fat and Ossification of the Posterior Longitudinal Ligament},
journal = {JBJS Open Access},
year = {2025},
volume = {10},
number = {4},
doi = {10.2106/jbjs.oa.25.00195}
}
EUVIMED